Zyvox

PROGRESS REPORTS Annual Report: Dependence Studies of New Compounds in the Rhesus Monkey 1979 ; M. D. Aceto; L. S. Harris; W. L. Dewey; E. L. May Annual Report: Biological Testing Program of the Committee on Problems of Drug Dependence, Inc. 1979 ; A. E. Jacobson Annual Report: Evaluation of New Compounds for Opioid Activity 1979 ; H. H. Swain; J. H. Woods; F. Medzihradsky; C. B. Smith; C. L. Fly PAPERS READ BY TITLE BUT NOT PRESENTED Effects of Alcohol Abuse on Progression of Liver Disease in Methadone-Maintained Patients C. L. Beverley; M. J . K Modification of Treatment Compliance as a Function of Contingent Payment Manipulations J. Grabowski; C. P. O'Brien; R. Greenstein; M. Long; S. Steinberg-Donato; J. Ternes The Effect of l-Alpha Acetyl Methadol in Morphine-Dependent Rats A. L. Riley; D. S. Etherton; R. M. Shapiro Outcome for Structural Family Therapy With Drug Addicts M. D. Stanton; T. C. Todd; F. Steier General Cardiovascular Pharmacology of 1 Acetylmethadol LAAM ; J. L. Stickney; D. C. Eikenburg; J. D. Keedy On the Relative Efficacy of LAAM and Methadone J. A. Whysner; D. B. Thomas; W. Ling; C. Charuvastra.

It can take a year or more and all you can do is be patient.

AOMT, the patients who developed MRSA otorrhea were treated with twice the number of courses of antibiotics. In these same patients, MRSA required 3 times the duration of antibiotic therapy. This finding underscores the importance of the judicious use of appropriate antibiotic therapy and the risks associated with prolonged use. The somewhat increased incidence of AOMT in patients with MRSA otorrhea suggests that colonization may persist after resolution of the clinical signs of infection, thus predisposing the patient to future recurrence. This also suggests that other potential sites of colonization that communicate with the middle ear eg, external auditory canal and nasopharynx ; may also need to be treated to eliminate the carriage of MRSA. Both of these hypotheses should be further examined in a prospective controlled design. Furthermore, the MRSA patients demonstrated similar trends. Although many of the episodes of MRSA otorrhea were treated effectively with ototopical drops, there may be a somewhat increased incidence of recurrent otorrhea in these patients. Our findings suggest that culture results and sensitivities may provide important prognostic information regarding future episodes of AOMT. At present, intravenous administration of vancomycin hydrochloride remains the drug of choice to treat MRSAinfected patients.28 As of March 1993, no vancomycinresistant strain of MRSA was reported in the literature.15 Unfortunately, in September 2002, a laboratory in Pennsylvania recorded the world's second case of vancomycinresistant S aureus.29 Fortunately, new antibiotics such as combined quinupristin and dalfopristin Synercid ; and linezolid Zzyvox ; have some activity against vancomycinresistant S aureus, although resistance to these agents has been detected. Vancomycin is often combined with other antibiotics in such cases.15 These other antibiotics include rifampin, novobiocin sodium, ciprofloxacin hydrochloride, combined trimethoprim sulfate and sulfamethoxazole, minocycline, and fusidic acid. In fact, 1 study30 found that patients with MRSA otorrhea received more than 1 type of antibiotic more frequently than did those with MSSA otorrhea. That notwithstanding, mere topical antibiotic therapy suffices in most cases of MRSA AOMT. It is the opinion of one of us J.E.D. ; that ototopical quinolones and cleocin. You become overweight when you take in more calories than you burn off with physical activity. This imbalance is believed to be influenced by a combination of genetic, environmental, psychological, and other factors. Obesity is measured by using a mathematical formula called a body mass index BMI ; weight in kilograms divided by height in meters squared BMI kg m2 ; . BMI of 19 to considered a "healthy weight target" and poses a minimal risk to your health, but a BMI higher than 26 begins to increase your risk for a variety of serious health problems. A BMI of 25 to 29.9 is considered overweight while 30 or above is considered obese.
Primarily involved either measurement of filtering rates of artificial seston by adults e.g., Kryger and Riisgard 1988; Silverman et al. 1997 ; or examination of filtering morphology e.g., Ward et al. 1993 ; . Gut content analyses of freshwater bivalves are rare and may be misleading because the method cannot distinguish ingested material that is not assimilated. Algae, for example, can survive passage through the digestive tract, and fecal material can have a high nitrogen content due to ingested material bypassing the stomach gland and moving directly to the intestinal tract Hawkins et al. 1983; Miura and Yamashiro 1990 ; . Also rare are energy budgets for freshwater bivalves. An energy budget for the fingernail clam Sphaerium striatinum was reported by Hornbach et al. 1984 ; , who estimated that 35% of its energy was derived from suspension feeding and the rest possibly from deposit feeding. Most stable isotope studies of food webs can be classed as either surveys of natural isotope abundance or experimental isotope enrichments. Natural abundances of stable carbon and nitrogen isotope ratios 13C and 15N ; have increasingly been used to examine the relative importance of various potential autotrophic sources in supporting food webs that include mollusks Incze et al. 1982; Peterson et al. 1985; Thorp et al. 1998 ; . Consumers tend to be enriched with the heavier stable isotope of nitrogen 15N ; relative to their diet Minagawa and Wada 1984 ; . Accounting for this trophic enrichment, unionids have been used to indicate the isotopic composition of the base of the food web in studies of lakes because they live long, have slow metabolism, and presumably utilize primary producers phytoplankton ; as their dominant food source. Unionids should thus integrate potential short-term fluctuations in primary producer isotope signatures over time Cabana and Rasmussen 1996 ; . This concept has been used to study the trophic position of fish in Canadian lakes and the effects of exotic species on food webs Vander Zanden et al. 1997, 1999 ; . 514 and minocin.

Contemporary adults thirst for variety and what's new, and our b-to-the-e delivers a beverage that is true to their lifestyles and range of drinking occasions, said pat mcgauley, senior director of new products and high end brands at a-b. 3.2 New Antibiotics. The first oxazolidinone, Zyvox, was approved in 2000 and is marketed by Pfizer. The antibiotic is approved for the treatment of bacteremia caused by vancomycin resistant Enterococcus faecium VREF ; , hospital acquired pneumonia, skin infections caused by methicillin resistant Staphylococcus aureus MRSA ; and bacteremia associated with community-acquired pneumonia due to penicillin susceptible Streptococcus pneumoniae. While Zycox has considerable activity against both Gram positive and Gram negative bacteria, it is only bacteriostatic, and does not show bacteriocidal activity. Also notable was the approval in 1999 of Synercid, which is a combination of quinupristin and dalfopristin. These two agents act synergistically to prevent protein synthesis by deactivating the bacterial ribosome. Synercid is approved for use against blood infections due to vancomycin resistant Enterococcus faecium VREF ; and skin infections caused by methicillin susceptible Staphylococcus aureus or Streptococcus pyogenes. Aventis won approval in April 2004 for Ketek, a member of the ketolide family of antibiotics. Ketolides are macrolide derivatives that act by attaching themselves to ribosomes and inhibiting protein synthesis While resistance to macrolides normally develops when the bacterium is able to alter the target site on the ribosome, Ketek binds to two different sites on the ribosome and so the development of resistance may be more difficult. Abbott has a ketolide in Phase III ABT-773 ; . In June 2005, Wyeth announced that the FDA approved TygacilTM tigecycline ; , a novel I.V. antibiotic with a broad spectrum of antimicrobial activity, including activity against the drug-resistant bacteria methicillinresistant Staphylococcus aureus MRSA ; . Tygacil is indicated for the treatment of complicated intra-abdominal infections cIAI ; and complicated skin and skin structure infections cSSSI ; in adults, and is described by Wyeth as a structurally distinct and re-engineered tetracycline. A modification of its core structure enables it to bind to the 30S ribosomal subunit with increased affinity compared with other tetracyclines. This allows it to overcome typical bacterial resistance to tetracyclines mediated by efflux pumps and ribosomal protection. Other approaches in development target different mechanisms. Cubist is marketing CubicinTM, which acts by interfering with bacterial cell wall synthesis. Microbiotix is targeting enzymes involved in DNA replication such as Polymerase III. Several companies are developing efflux pump inhibitors to prevent the removal of antibiotics, lactoferrins that deprive bacteria of nutrients, and cationic peptides to compromise cell wall integrity. Oscient has recently begun selling Factive, an orally administered quilnolone that works by inhibiting two specific enzymes, DNA gyrase and DNA topoisomerase IV, which aid in bacterial DNA replication and tetracycline. The chance of serious infection is greatest if the shop doesn't use sterile technique and take body fluid precautions. Linezolid. The results are summarized in Table 1. As shown in the same Table, the good activity of aurein 1.2 was confirmed by the MBC values range of 2-64 mg l ; comparable to those of other antibiotics. At concentration of 2MIC, killing activities of aurein 1.2 on staphylococci, enterococci and streptococci were complete after 30, 40 and 20 min exposure period and minocycline.
Chronic Osteomyelitis Not FDA approved ; Bibliography 1. Zvyox linezolid ; US Drug Package Insert, Dec 2002. 2. Zyvox linezolid ; Drug Facts and Comparisons. St Louis, MO: Facts and Comparisons, 2003 3. Mosby's Drug Consult, 2004, available at mdconsult 4. Rao N. Treatment of chronic osteomyelitis with linezolid [Abstract #195]. Proceedings of the 40th Annual Meeting of the Infectious Disease Society of America IDSA 2002 October 24-27; Chicago, Illinois. 5. Tagliaferri E, Lucarini A, Leonildi A, et al: Treatment of bone and prosthetic joint infections with linezolid [Abstract]. Proceedings of the 12th European Congress of Clinical Microbiology and Infectious Diseases ECCMID 2002 April 24-27; Milan, Italy. 6. Till M, Wixson RL, Pertel PE. Linezolid treatment for osteomyelitis due to vancomycinresistant Enterococcus faecium. Clin Infect Dis 2002; 34: 1412-1413. Micromedex HealthCare Series, Drugdex 2005 8. Centers for Disease Control and Prevention. National Diabetes Fact Sheet. Available at: : cdc.gov diabetes pubs general . Accessed November 26, 2003. 9. Levin ME. Management of the diabetic foot: preventing amputation. South Med J. 2002: 95: 10-20. Caputo GM, Cavanaugh PR. Ulbrecht JS. Gibbons GW. Karcbmer AW. Assessment and management of foot disease in patients with diabetes. N Engl J Med. 1994: 331: 854-860. Wheat LJ. Aleen SD, Henry M, ee al. Diabetic foot infections. Bacteriologic analysis. Arch intern Med. 1986; 146: 1935-1940. Baquem F. Gram-positive resistance: challenge for the development of new antibiotics. 1997: 1-4. 13. Dang CN, Prasad YD. Bouloon AJ. Jude EB. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med. 2003: 20: 159-161. Wagner A, Reike H, Angelkort. B. Highly resistant pathogens, especially methicillinresistant Staphylococcus aureus, in diabetic patients with foot infections. Disch Med Worchenschr. 2001: 126: 1353-1356 Singhal A. Reis ED, Kerstein MD. Options for nonsurgical debridement of necrotic wounds. Adv Slein Wound Care. 2001: 14: 96-103. Boulton AJ. Meneses P. Ennis WJ. Diabetic foot ulcers: a framework for prevention and care. Wound Rep Reg. 1999: 7: 7-16. mg IV or oral q 12h up to 15 weeks. 3.5.1.AV Levomethadyl 1 ; Interaction Effect: an increased risk of cardiotoxicity QT prolongation, torsades de pointes, cardiac arrest ; 2 ; Summary: Any drug known to have the potential to prolong the QT interval should not be used with levomethadyl. Possible pharmacodynamic interactions can occur between levomethadyl and potentially arrhythmogenic agents such as risperidone that prolong the QT interval Prod Info Orlaam R ; , 2001 ; . 3 ; Severity: contraindicated 4 ; Onset: delayed 5 ; Substantiation: theoretical 6 ; Clinical Management: Levomethadyl is contraindicated in patients being treated with risperidone as it may precipitate QT prolongation and interact with levomethadyl. 7 ; Probable Mechanism: additive cardiac effects 3.5.1.AW Levorphanol 1 ; Interaction Effect: precipitation of opioid withdrawal symptoms in opioid-dependent patients 2 ; Summary: A patient stabilized on levorphanol 14 mg daily for neck pain experienced opioid cravings and cramps following three days of risperidone therapy. Discontinuing risperidone resolved her symptoms of withdrawal. Possible mechanisms for this effect include risperidone accelerating opioid metabolism via the cytochrome P450 system, interference with the gastrointestinal absorption or secretion of the opioid, altered opioid distribution, or opioid displacement from plasma protein binding sites Wines & Weiss, 1999a ; . 3 ; Severity: moderate 4 ; Onset: delayed 5 ; Substantiation: probable 6 ; Clinical Management: Opioid-dependent patients should be monitored for signs of opioid withdrawal if risperidone is concurrently prescribed. 7 ; Probable Mechanism: unknown 8 ; Literature Reports a ; A 31-year-old female with a lengthy history of drug dependency, including opioids, was being treated with fluoxetine 40 mg daily for depression and levorphanol 14 mg daily for chronic severe neck pain. Because of recurring nightmares and flashbacks, risperidone 0.5 mg daily was initiated and increased to 1.5 mg daily within two days. While her dissociative symptoms improved, she complained of cramps, gooseflesh, and opioid cravings. Risperidone was decreased to 1 mg daily but her dissociative symptoms worsened. Her risperidone was again increased to 2 mg daily, but she experienced an increase in her withdrawal symptoms which persisted for days. Risperidone therapy was eventually discontinued Wines & Weiss, 1999 ; . 3.5.1.AX Lidoflazine 1 ; Interaction Effect: an increased risk of cardiotoxicity QT prolongation, torsades de pointes, cardiac arrest ; 2 ; Summary: Lidoflazine has been shown to prolong the QTc interval at the recommended therapeutic dose Hanley & Hampton, 1983 ; . Even though no formal drug interaction studies have been done, the coadministration of antipsychotics and other drugs known to prolong the QTc interval is not recommended. Several antipsychotic agents have demonstrated QT prolongation including amisulpride Prod Info Solian R ; , 1999 ; , haloperidol O'Brien et al, 1999 ; , quetiapine Owens, 2001 ; , risperidone Duenas-Laita et al, 1999 ; , sertindole Agelink et al, 2001 ; , sultopride Lande et al, 1992 ; , and zotepine Sweetman, 2003 ; . 3 ; Severity: major 4 ; Onset: unspecified 5 ; Substantiation: theoretical 6 ; Clinical Management: The concurrent administration of lidoflazine and antipsychotics is not recommended. 7 ; Probable Mechanism: additive cardiac effects 3.5.1.AY Linezolid 1 ; Interaction Effect: increased risk of serotonin syndrome hyperthermia, hyperreflexia, myoclonus, mental status changes ; 2 ; Summary: In a review of post-marketing data, 1 case of serotonin toxicity was reported with the concurrent use of linezolid and risperidone, which was coadministered with other serotonergic agents Lawrence et al, 2006 ; . Risperidone, in combination with other serotonergic agents, has been associated with the serotonin syndrome Springuel & McMorran, 2003 ; . Although coadministration of linezolid and serotonergic agents did not result in serotonin syndrome in phase 1, 2, or 3 clinical trials, linezolid is a reversible, non-selective MAOI and can potentially interact with serotonergic agents, precipitating the serotonin syndrome. If concurrent use of linezolid and a serotonergic agent is clinically warranted, monitor patients closely for signs and symptoms of serotonin syndrome, such as cognitive dysfunction, hyperpyrexia, hyperreflexia, and incoordination. Consider discontinuing either one or both agents if these symptoms occur, keeping in mind that discontinuation of the concomitant serotonergic agent may result in associated discontinuation symptoms Prod Info ZYVOX R ; injection, tablets, oral suspension, 2005 ; . 3 ; Severity: major 4 ; Onset: unspecified 5 ; Substantiation: probable 6 ; Clinical Management: Serotonin toxicity has been reported in 1 individual with the concurrent use of linezolid and risperidone, which was coadministered with other serotonergic agents. If concurrent use of linezolid and risperidone, particularly with additional serotonergic agents, is clinically necessary, monitor patients closely for signs and symptoms of serotonin syndrome, such as cognitive dysfunction, hyperpyrexia, hyperreflexia, and incoordination. Consider discontinuing either one or both agents if these symptoms occur, keeping in mind that discontinuation of the concomitant serotonergic agent may result in associated discontinuation symptoms. 7 ; Probable Mechanism: potentiation of serotonergic activity 8 ; Literature Reports a ; In a review of post-marketing data, 1 case of serotonin toxicity were reported in the concurrent use of linezolid and risperidone, which was coadministered with other serotonergic agents. A review was conducted of post-marketing adverse events reported to the US Food and Drug Administration's Adverse Event Reporting System AERS ; database and doxycycline. Jones, R. N., J. E. Ross, T. R. Fritsche, and H. S. Sader. 2006. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox R ; Annual Appraisal of Potency.
Nowadays the creation of animations is straightforward, and it already works on a small scale without advanced computer skills. Today we have available convenient and low-priced software, which allows realizing of animations. Today's hardware is also good enough to present detailed animations, which are complex and highly functional. The educational advantage gained from the animations must be great enough to make its costs acceptable. In our case the animations produced were very simple and they were designed beforehand on the basis of the lecture material. Thus the production costs remained low compared to the benefits. If it is not possible to use pre-designed material, then we must take into account the time needed for the design of the animations. Our experiences of the use of the animations produced encourage us to continue this kind production in the future. The students' feedback was very positive and nearly all the students regarded the animations as useful. Especially the lecturer considered that the animations facilitated his work in many ways. Thus we can conclude that at least and ethionamide and Buy cheap zyvox. Other adverse events reported in phase 2 and phase 3 studies included oral moniliasis, vaginal moniliasis, hypertension, dyspepsia, localized abdominal pain, pruritus, and tongue discoloration. Table 6 shows the incidence of drug-related adverse events reported in at least 1% of patients in these trials by dose of ZYVOX. Laboratory Changes ZYVOX has been associated with thrombocytopenia when used in doses up to and including 600 mg every 12 hours for up to 28 days. In phase 3 comparator-controlled trials, the percentage of patients who developed a substantially low platelet count defined as less than 75% of lower limit of normal and or baseline ; was 2.4% range among studies: 0.3 to 10.0% ; with ZYVOX and 1.5% range among studies: 0.4 to 7.0% ; with a comparator. Thrombocytopenia associated with the use of ZYVOX appears to be dependent on duration of therapy, generally greater than 2 weeks of treatment ; . The platelet counts for most patients returned to the normal range baseline during the follow-up period. No related clinical adverse events were identified in phase 3 clinical trials in patients developing thrombocytopenia. Bleeding events were identified in thrombocytopenic patients in a compassionate use program for ZYVOX; the role of linezolid in these events cannot be determined see PRECAUTIONS ; . Changes seen in other laboratory parameters, without regard to drug relationship, revealed no substantial differences between ZYVOX and the comparators. These changes were generally not. Vertigo dizziness ; of various origins such as: arteriosclerosis cervical spine syndrome circulatory insufficiency tinnitus nausea and motion sickness over 40 years of therapeutic use and recommended by ent doctors in more than 90 countries and erythromycin. Education Program Adult Treatment Panel III NCEP ATP III ; 10 and the American Diabetes Association ADA ; 12 highlight the importance of LDL-cholesterol reduction in high risk patients, but at the same time encourage physicians to position all patients with type 2 diabetes and insulin resistance in the high cardiovascular risk category. Because patients with type 2 diabetes and insulin resistance are commonly affected by the atherogenic dyslipidemia, characterized by high triglycerides and low HDLcholesterol, one could argue that the optimal lipid intervention in these patients should be one targeting these abnormalities. Triglyceride and HDLcholesterol levels have been shown to predict coronary event rates independently from LDLcholesterol levels in populations from Europe and the US. 13-15 The knowledge that the ratio of total cholesterol to HDL-cholesterol is the most sensitive index of cardiovascular disease progression highlights the important contribution of atherogenic dyslipidemia to cardiovascular risk, given that this ratio is mostly determined by abnormalities of triglyceride metabolism. This is reflected in the current NCEP ATP III guidelines, which suggest a secondary goal of non-HDL-cholesterol to be only 30mg dL higher than that for LDL-cholesterol.10 A subject whose LDL-cholesterol is already at goal but has an inappropriate level of non-HDL cholesterol is a subject affected by hypertriglyceridemia. Thus, current guidelines support aggressive treatment of triglycerides in the high risk patient.10 Indeed, normalization of the entire lipid profile is becoming the ultimate goal for optimal risk reduction in the high-risk individual.

Add Rifampin to above regimen 300 mg p.o. twice daily x five days. Intranasal and under the fingernail treatment with either bacitracin ointment or mupirocin Bactroban ; ointment twice daily x five days. 5% povidone iodine cream intranasally four times a day x five days. Showers with chlorhexidine Hibiclens ; daily x three days and then three times weekly. Household and close contact treated treat by case decisions ; with mupirocin ointment to the anterior nostrils twice daily x five days. Reserve vancomycin, linezolid Zyvox ; , daptomycin Cubicin ; and quinupristindalfopristin Synercid ; for severe cases. Note.1 Compared to pre-surgical baseline p , .025 ; . 2 Compared to 2nd evaluation p , 0.025 ; . 3 Bilateral DBS vs. pre-surgical baseline. BDAE-CIM 5 Boston Diagnostic Aphasia Examination, Complex Ideational Material; BNT 5 Boston Naming Test; BVMT-R 5 Brief Visuospatial Memory TestRevised; RAVLT 5 Rey Auditory Verbal Learning Test; WAIS-R 5 Wechsler Adult Intelligence TestRevised.
Definitive large-scale trials to investigate the antihypertensive effects of lipid-lowering drugs are required, although end point studies examining the interaction of lipid-lowering and antihypertensive drugs to determine optimum combinations are already under way and buy myambutol. To get enough of these two vitamins, follow the united states department of agriculture's food guide pyramid recommendations 12. The FDA approved Zyvox linezolid ; , the first of a new class of antibiotics called oxazolidinones. See T. Hayden, "Infectious Arms Race, " U.S. News & World Report, Dec. 17, 2001, at 50. 169. See 65 Fed. Reg. 81, 082, 81, ; proposing revisions in the content of prescription drug labeling to reduce the tendency to overprescribe antibiotics 65 Fed. Reg. 56, 511, 56, ; proposing a best practices statement in the labeling of antibiotics to remind physicians against overprescribing ; . 170. See S.B. Markow, Note, "Penetrating the Walls of DrugResistant Bacteria: A Statutory Prescription to Combat Antibiotic Misuse, " Georgetown Law Journal, 87 1998 ; : 53162, at 546 47 suggesting that only infectious disease specialists in hospitals be permitted to use new antibiotics ; . 171. See 65 Fed. Reg. 24, 704, 24, ; "How should the risks and benefits to individuals and risks and benefits to the public health be assessed and weighed in any decision on OTC marketing? For example, how should the agency balance the potential benefits of OTC antimicrobial agents with the potential risks to society at large of the development of resistant organisms associated with increased, and potentially improper, use?" ; . 172. See L. Noah, "Medicine's Epistemology: Mapping the Haphazard Diffusion of Knowledge in the Biomedical Community, " Arizona Law Review, 44 2002 ; : 373466, at 43842; see also T.J. Moore et al., "Time to Act on Drug Safety, " JAMA, 279 1998 ; : 157173, at 1572 "[N]ew warnings about the addictive properties of propoxyphene had no effect on either prescription volume or the number of overdose deaths." ; . 173. See R. Gonzales et al., "Principles of Appropriate Antibiotic Use for Treatment of Acute Respiratory Tract Infections in Adults: Background, Specific Aims, and Methods, " Annals of Internal Medicine, 134 2001 ; : 47986, at 48182 introducing a series of CDC guidelines calling for restraint in prescribing antibiotics for adults see also T. Brewer and G.A. Colditz, "Postmarketing Surveillance and Adverse Drug Reactions: Current Perspectives and Future Needs, " JAMA, 281 1999 ; : 82429, at 826 describing the CDC's vaccine adverse event surveillance efforts ; . See generally E.W Etheridge, Sentinel for Health: A His. tory of the Centers for Disease Control Berkeley: Univ. of California Press, 1992 L.O. Gostin, Public Health Law: Power, Duty, Restraint Berkeley: Univ. of California Press, 2000 L. Noah, "Triage in the Nation's Medicine Cabinet: The Puzzling Scarcity of Vaccines and Other Drugs, " South Carolina Law Review, 54 forthcoming 2003 ; . 174. See Thompson v. Western States Med. Ctr., 535 U.S. 357 2002 ; invalidating a restriction on advertising by pharmacists who compound drug products L. Noah, "What's Wrong with `Constitutionalizing Food and Drug Law, '" Tulane Law Review, 75 2000 ; : 13748 discussing litigation challenging the FDA's restrictions on indirect industry efforts to promote off-label drug uses ; . 175. See OxyContin -- It's Use and Abuse: Hearing Before the Subcomm. on Oversight & Investigations of the House Comm. on Energy & Commerce, 107th Cong., at 9 2001 ; statement by Terrance W Woodworth, Deputy Director, DEA Office of Diver. sion Control ; "[T]he five states with the lowest number of per capita OxyContin prescriptions all have long standing prescription monitoring programs in place." see also D. Brushwood, "Maximizing the Value of Electronic Prescription Monitoring Programs, " Journal of Law, Medicine & Ethics, 31 2003 ; : 4154. Doctors and drug companies generally oppose such programs. See M. Petersen & B. Meier, "Few States Track Prescriptions as Way to Prevent Overdoses, " New York Times, Dec. 21, 2001, at A1. 176. See J. Avorn & S.B. Soumerai, "Improving Drug-Therapy Decisions Through Educational Outreach: A Randomized Controlled Trial of Academically Based `Detailing, '" N. Engl. J. Med. One such company is Arpida, who are in Phase III development of the DHFR inhibitor iclaprim for the treatment of antibiotic-resistant staphylococcal complicated skin and skin structure infections, or cSSI. At ICAAC, Arpida reported full data from the pivotal ASSIST-1 trial, which compared iclaprim with Pfizer's Zyvox. Iclaprim was shown to have high microbiological eradication rates against major cSSI pathogens, with MRSA eradication rates of 84.7% versus 85.3% for Zyvox. So, ASSIST-1 shows us that iclaprim is non-inferior to Zyvox. Also, iclaprim could offer significant clinical benefits over Zyvox which can cause myelosuppression; as a result patients need regular blood monitoring with Zyvox. Importantly, Arpida also presented Phase I data at ICAAC on both intravenous and oral iclaprim. Results showed that iclaprim exhibited extensive tissue distribution, showed good oral bioavailability and was well-tolerated. Currently, Zyvox is the only cSSI treatment available in both oral and iv formulations. Overall, we're really positive about iclaprim's future.